Risk Stratification Testing for Melanoma
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Derek Maetzold, president and CEO of Castle Biosciences, discusses the importance of personalized management and treatment approaches for patients diagnosed with melanoma, and how gene expression profile testing can help.
Overview
Derek Maetzold, president and CEO of Castle Biosciences, discusses the importance of personalized management and treatment approaches for patients diagnosed with melanoma, and how gene expression profile testing can help.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
HF Management for Patients with Comorbid Conditions
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?